[NuTide:302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment

Administered By

Awarded By

Contributors

Start/End

  • March 16, 2022 - March 6, 2027